NCT03875157: Study of IBI318 in Participants With Advanced Malignancies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase (not the expansion phase), unless patient had therapeutic effect from Phase Ia
Exclusions: Patients with known active untreated CNS metastases, spinal cord compression, or cancerous meningitis; Patients previously exposed to immunotherapies- see trial for details

Comments are closed.

Up ↑